GE HealthCare price target raised to $97 from $86 at BofA

BofA analyst Craig Bijou raised the firm’s price target on GE HealthCare to $97 from $86 and keeps a Neutral rating on the shares. The China stimulus rollout seems to be moving forward, but “at a pace much slower than the previous one,” says the analyst, who would not expect a meaningful impact on orders or sales in 2024. Sales should follow orders in 2025 and probably extend into 2026, says the analyst, who continues to believe that the China stimulus is a long-term tailwind for GE HealthCare, but says limited near-term visibility adds risk.